• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

The 3C Study: Alemtuzumab may reduce acute rejection following kidney transplant

bySarah StapletonandChaz Carrier
August 2, 2014
in Chronic Disease, Nephrology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Alemtuzumab induction treatment significantly reduced events of biopsy-proven acute rejection (BPAR) when compared with standard basiliximab-based therapy (BBT). 

2. Kidney graft function at six months was not significantly different between the two therapy regimes. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Acute antibody-mediated or cellular rejection affects approximately 16% of kidney transplant patients following standard BBT (basiliximab followed by standard-dose tacrolimus, mycophenolate, and prednisolone). Observations suggest such acute rejection events may predict higher risk of ultimate graft failure. Previous studies have separately suggested substitution of alemtuzumab for basiliximab, and lower doses of calcineurin inhibitors (e.g. tacrolimus) may reduce acute rejection events.

This randomized study of 852 kidney transplant patients compared acute rejection rates between standard BBT and alemtuzumab-based treatment (ABT: alemtuzumab followed by low-dose tacrolimus and mycophenolate without steroids). Six months post transplantation, ABT resulted in a nearly 60% reduction in BPAR events: 7% of patients treated with ABT and 16% of patients treated with BBT had experienced BPAR. While the number of ABT patients suffering from cellular BPAR was less than half that of B20 patients, no significant between-group difference was found for antibody-mediated BPAR events. Despite reduced BPAR risk, graft function was not significantly improved in ABT patients.

This study varied induction treatment type, tacrolimus dosage and steroid presence across the two therapy regimes, making it difficult to identify whether individual or synergistic effects are behind early ABT success. Long-term results from this continuing study will help evaluate the relationship between acute rejection and lasting transplant survival.

Click to read the study in The Lancet

RELATED REPORTS

#VisualAbstract: Perioperative dexmedetomidine decreases the incidence of select complications following kidney transplantation

Perioperative dexmedetomidine decreases the incidence of select complications following kidney transplantation

#VisualAbstract Half of the organ transplant recipients who develop skin cancers post-transplant will develop at least another skin cancer within two years

Click to read an accompanying editorial in The Lancet

Relevant Reading: Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation

In-Depth [randomized controlled trial]: This randomized, open-label, multicenter study of 852 kidney transplant patient compared BBT and ABT in their ability to reduce acute rejection events. Patients over the age of 18 and within 24 hours of transplantation surgery were recruited to the study. One half of the patient group was allocated to ABT, the other half to BBT. The minimization method was used to balance patient and donation characteristics across the two cohorts. Specific dosage amounts and times for each post-transplantation treatment regime are detailed in the original article. Event rate ratios were determined by Cox proportional hazards model and two-sided p-value significance was evaluated by log-rank test. The findings of this study consider results from the initial six-month post-transplantation period.

ABT patients had a significantly reduced risk of BPAR within six months of kidney transplant when compared to BBT patients (Hazard ratio (HR) = 0.42, p < 0.0001). BPAR occurred in 68 BBT patients and 31 ABT patients. The ABT reduction in total BPAR is attributed to cellular BPAR events (HR = 0.37, p < 0.0001), and not antibody-mediated BPAR events (HR = 1.59, p = 0.41). ABT patients had increased occurrence of leucopenia though no significant difference was found for serious infections or deaths. ABT was not found to improve graft function at six months.

More from this author: Chemokines in cardiac allografts promote graft rejection in mice, Modulating lymphocyte populations decreases graft rejection in mice,Adding Evolocumab to statin therapy further decreases LDL-C levels,Genetic variant linked to poor patient survival following lung transplantation, Neuroendocrine tumor marker pancreastatin may be predictive of survival

Image: PD 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: Alemtuzumabkidney transplant
Previous Post

Tumor response ratio may predict survival following neoadjuvant chemotherapy in breast cancer

Next Post

Economic incentives effective in increasing male circumcision rates in Kenya

RelatedReports

#VisualAbstract: Perioperative dexmedetomidine decreases the incidence of select complications following kidney transplantation
StudyGraphics

#VisualAbstract: Perioperative dexmedetomidine decreases the incidence of select complications following kidney transplantation

June 15, 2022
Patient Basics: Kidney Transplant
Chronic Disease

Perioperative dexmedetomidine decreases the incidence of select complications following kidney transplantation

June 9, 2022
#VisualAbstract Half of the organ transplant recipients who develop skin cancers post-transplant will develop at least another skin cancer within two years
StudyGraphics

#VisualAbstract Half of the organ transplant recipients who develop skin cancers post-transplant will develop at least another skin cancer within two years

October 29, 2021
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

Postponing renal replacement therapy may result in poor clinical outcomes in patients with severe acute kidney injury 

June 25, 2021
Next Post
Economic incentives effective in increasing male circumcision rates in Kenya

Economic incentives effective in increasing male circumcision rates in Kenya

Classics Series, Landmark Trials in Medicine

The CARESS trial: Dual antiplatelet therapy superior to monotherapy in symptomatic carotid stenosis [Classics Series]

New dengue fever vaccine effective in phase 3 trial

2 Minute Medicine Rewind July 27 – August 3, 2014

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Relugolix combination therapy is efficacious for endometriosis-associated pain
  • Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination
  • OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.